ACUTE MYELOID LEUKEMIA (AML)

This early-phase study tests a new treatment called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) to find and attack cancer cells. The main goals ar…

This early-stage study tests a new treatment called universal CD7 CART cells for people with relapsed or hard-to-treat blood cancers that carry a specific marker (CD7). The therapy uses specially engineered immune cells from a donor to attack cancer cells. The main goals are to c…

This study tests a new treatment for people with certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard therapy. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from a dono…

This early-stage study tests a new drug called STX-0712 in people with advanced chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) who have run out of standard treatments. The main goals are to find a safe dose and check for side effects. About 105 participant…

This study tests if adding an experimental drug called ziftomenib to standard chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) live longer or achieve remission. About 1,300 adults with untreated AML and certain gene changes will receive eithe…

This study tests whether a daily pill called ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either the drug or a placebo. The goal is to see if the drug extend…

This study tests a new way to prepare people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) for a stem cell transplant. Instead of standard full-body radiation, participants receive targeted proton radiation to the bone marrow, combined with chemoth…

This study tests whether a newer drug, gilteritinib, works better than the current standard, sorafenib, to prevent leukemia from coming back after a stem cell transplant. About 594 adults and teens with a specific genetic mutation (FLT3-ITD) will be randomly assigned to take one …

This study tests the safety of combining ivosidenib and azacitidine in adults newly diagnosed with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML) who are not healthy enough for intensive chemotherapy. About 245 participants will receive the drug combination …

This study tests whether two drugs, azacitidine and venetoclax, can eliminate or reduce leftover leukemia cells (called measurable residual disease) in adults with acute myeloid leukemia who are scheduled for a donor stem cell transplant. About 30 participants will receive the dr…

This study is for people with a type of blood cancer called acute myeloid leukemia (AML) that has come back or not responded to treatment. The cancer must have specific gene changes (FLT3 and IDH1 or IDH2). The study tests a combination of two targeted drugs (gilteritinib plus iv…

This study tests a new combination of drugs (bendamustine and cyclophosphamide) to prevent graft-versus-host disease and a dangerous immune reaction after a stem cell transplant. It includes 60 adults with high-risk blood cancers like acute myeloid leukemia or myelodysplastic syn…

This study tests a new treatment called supCD7 CART cells for people with certain blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia) that have come back or not responded to standard therapy. The cells are designed to find and attack cancer cells that carry a prote…

This early-stage study tests an experimental drug called APL-4098, alone or with standard chemotherapy drugs, in about 100 adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to treatment. The main goals are to check safety, find…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This study tests whether adding metal-detoxifying drugs (Ca-EDTA and DMSA) to standard chemotherapy can help control acute myeloid leukemia (AML) in adults. Researchers believe that lowering certain metals in the blood and bone marrow may improve how well the cancer responds to t…

This study tests a new drug combination called VABu given before a stem cell transplant in people aged 60 and older with acute myeloid leukemia (AML). The goal is to see if this approach can help control the disease and improve survival. About 20 participants will receive the VAB…

This early-stage trial tests niclosamide (a drug used for tapeworm infections) combined with standard chemotherapy in children whose acute myeloid leukemia (AML) has returned or not responded to prior treatments. The main goal is to find a safe dose and check for side effects. Up…

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This study tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) in adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated) who cannot tolerate strong chemotherapy. The goal is to see if this tre…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This study is a registry that gathers medical data and biological samples from 15,000 adults with acute myeloid leukemia (AML) at 60 hospitals in Germany. It aims to track patient characteristics, treatments, and long-term outcomes like survival and relapse. No new treatments are…

This study follows 100 adults with acute myeloid leukemia who have had a stem cell transplant. Researchers use a highly sensitive DNA test (digital PCR) to look for tiny amounts of leukemia-related mutations in the blood at several time points during the first year after transpla…

This study is a long-term observation of 1,000 patients receiving stem cell transplants for blood diseases at a hospital on the Qinghai-Tibet Plateau. Researchers will collect information on patient health, treatment results, and costs to understand how high altitude affects reco…

This study will follow 5,000 adults with acute myeloid leukemia (AML) in French hospitals to see how they are treated and how they do over time. It does not test a new drug but collects information on current treatments and survival rates. The goal is to learn more about real-lif…

This study looks at whether measuring leukemia stem cells can help predict if acute myeloid leukemia (AML) with MLL rearrangement will come back. Researchers will test bone marrow samples from 210 patients aged 6-60 who are receiving chemotherapy or a stem cell transplant. The go…

This study is a large registry that will follow up to 50,000 adults with acute myeloid leukemia (AML) or related blood cancers for up to 10 years. Researchers will collect medical history, genetic markers, and treatment outcomes to better understand the disease and improve future…